[PDF][PDF] Point mutation of the proteasome b5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell …

S Lu, J Yang, X Song, S Gong, H Zhou, L Guo… - J Pharmacol Exp …, 2008 - Citeseer
To study the mechanism of acquired resistance to bortezomib, a new antitumor drug that is
the first therapeutic proteasome inhibitor, we established a series of bortezomib-resistant T …

Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic …

S Lü, J Yang, X Song, S Gong, H Zhou, L Guo… - … of Pharmacology and …, 2008 - ASPET
To study the mechanism of acquired resistance to bortezomib, a new antitumor drug that is
the first therapeutic proteasome inhibitor, we established a series of bortezomib-resistant T …

[HTML][HTML] Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

S Lü, J Yang, Z Chen, S Gong, H Zhou, X Xu… - Experimental …, 2009 - Elsevier
OBJECTIVE: To investigate the relationship between bortezomib resistance and mutations
in the proteasome β5 subunit (PSMB5) gene. MATERIALS AND METHODS: Various …

[HTML][HTML] The resistance mechanisms of proteasome inhibitor bortezomib

S Lü, J Wang - Biomarker research, 2013 - Springer
The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the
chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy …

[HTML][HTML] Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

S Lü, Z Chen, J Yang, L Chen, S Gong, H Zhou… - Experimental …, 2008 - Elsevier
OBJECTIVE: To study the mechanism of bortezomib resistance in JurkatB lines derived from
T-lymphoblastic lymphoma/leukemia Jurkat line. MATERIALS AND METHODS …

Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein

R Oerlemans, NE Franke, YG Assaraf… - Blood, The Journal …, 2008 - ashpublications.org
The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in
the treatment of refractory multiple myeloma. However, its clinical efficacy has been …

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

NE Franke, D Niewerth, YG Assaraf, J van Meerloo… - Leukemia, 2012 - nature.com
Proteasome inhibition is a novel treatment for several hematological malignancies.
However, resistance to the proteasome inhibitor bortezomib (BTZ, Velcade) is an emerging …

Proteasome subunits differentially control myeloma cell viability and proteasome inhibitor sensitivity

CX Shi, YX Zhu, LA Bruins, C Bonolo de Campos… - Molecular Cancer …, 2020 - AACR
We generated eight multiple myeloma cell lines resistant to bortezomib; five acquired
PSMB5 mutations. In 1,500 patients such mutations were rare clinically. To better …

Novel proteasome inhibitors to overcome bortezomib resistance

AM Ruschak, M Slassi, LE Kay… - Journal of the National …, 2011 - academic.oup.com
The proteasome is an intracellular enzyme complex that degrades ubiquitin-tagged proteins
and thereby regulates protein levels within the cell. Given this important role in maintaining …

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

DI Lichter, H Danaee, MD Pickard… - Blood, The Journal …, 2012 - ashpublications.org
Variations within proteasome β (PSMB) genes, which encode the β subunits of the 20S
proteasome, may affect proteasome function, assembly, and/or binding of proteasome …